Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.